Expression and clinical role of the dipeptidyl peptidases DPP8 and DPP9 in ovarian carcinoma
- 53 Downloads
Dipeptidyl peptidase 9 (DPP9) was recently identified as fusion gene in ovarian high-grade serous carcinoma (HGSC). The aim of this study was to analyze the expression and clinical relevance of DPP8 and DPP9 in ovarian carcinoma, with focus on HGSC. mRNA expression by qRT-PCR of DPP8 and DPP9 was analyzed in 232 carcinomas, including 114 effusions and 118 surgical specimens (89 ovarian, 29 solid metastases). DPP8 and DPP9 protein expression was analyzed in 92 effusions. DPP8 and DPP9 mRNA was overexpressed in effusions compared to solid lesions in analysis of all histotypes (p < 0.001 both), as well as in analysis limited to HGSC (p < 0.001 for DPP9, p = 0.002 for DPP8). DPP9 mRNA was additionally overexpressed in HGSC compared to other histotypes (p = 0.021). DPP8 and DPP9 protein was expressed in carcinoma cells in 31/92 (37%) and 81/92 (88%) effusions, respectively. DPP8 protein expression in HGSC effusions was significantly related to better (complete) chemoresponse at diagnosis (p = 0.005). DPP8 and DPP9 mRNA and protein expression was unrelated to survival in analysis of the entire effusion cohort. However, higher DPP9 mRNA levels were significantly related to longer overall survival in pre-chemotherapy effusions (p = 0.049). In conclusion, DPP8 and DPP9 mRNA is frequently expressed in ovarian carcinoma, whereas DPP9 is more frequently expressed at the protein level. DPP8 and DPP9 may be related to less aggressive disease in advanced-stage HGSC.
KeywordsOvarian carcinoma Dipeptidyl peptidases Disease progression Survival Immunohistochemistry Quantitative PCR
MB performed the PCR experiments and wrote the manuscript.
AH performed the IHC experiments.
IP participated in performing the PCR experiments and critically read the manuscript.
ACS provided clinical data and specimens and critically read the manuscript.
FM designed the study, supervised the PCR experiments, and critically read the manuscript.
BD designed the study, performed the statistical analysis, scored the immunostains, and supervised the writing of the manuscript.
This work was supported by The Inger and John Fredriksen Foundation for Ovarian Cancer Research. Marta Brunetti is supported by a grant from the South-East Health Region of Norway.
Compliance with ethical standards
The study was approved by the Regional Committee for Medical Research Ethics in Norway.
Conflict of interest
The authors declare that they have no conflict of interest.
- 3.Davidson B (2018) Ovarian carcinoma. In: Davidson B, Firat P, Michael CW (eds) Serous effusions - etiology, diagnosis, prognosis and therapy, 2nd edn. Springer, LondonGoogle Scholar
- 4.Kurman RJ, Carcangiu ML, Herrington CS, Young RH (2014) WHO classification of tumors of female reproductive organs. IARC, LyonGoogle Scholar
- 10.Hoogstraat M, de Pagter MS, Cirkel GA, van Roosmalen MJ, Harkins TT, Duran K, Kreeftmeijer J, Renkens I, Witteveen PO, Lee CC, Nijman IJ, Guy T, van 't Slot R, Jonges TN, Lolkema MP, Koudijs MJ, Zweemer RP, Voest EE, Cuppen E, Kloosterman WP (2014) Genomic and transcriptomic plasticity in treatment-naive ovarian cancer. Genome Res 24:200–211CrossRefGoogle Scholar
- 15.Tang Z, Li J, Shen Q, Feng J, Liu H, Wang W, Xu L, Shi G, Ye X, Ge M, Zhou X, Ni S (2017) Contribution of upregulated dipeptidyl peptidase 9 (DPP9) in promoting tumoregenicity, metastasis and the prediction of poor prognosis in non-small cell lung cancer (NSCLC). Int J Cancer 140:1620–1632CrossRefGoogle Scholar
- 16.Kajiyama H, Kikkawa F, Khin E, Shibata K, Ino K, Mizutani S (2003) Dipeptidyl peptidase IV overexpression induces up-regulation of E-cadherin and tissue inhibitors of matrix metalloproteinases, resulting in decreased invasive potential in ovarian carcinoma cells. Cancer Res 63:2278–2283PubMedGoogle Scholar
- 18.Mhawech-Fauceglia P, Yan L, Sharifian M, Ren X, Liu S, Kim G, Gayther SA, Pejovic T, Lawrenson K (2015) Stromal expression of fibroblast activation protein alpha (FAP) predicts platinum resistance and shorter recurrence in patients with epithelial ovarian cancer. Cancer Microenviron 8:23–31CrossRefGoogle Scholar